Musculoskeletal disorders as underlying cause of death in 58 countries, 1986–2011: trend analysis of WHO mortality database by unknown
RESEARCH ARTICLE Open Access
Musculoskeletal disorders as underlying
cause of death in 58 countries, 1986–2011:
trend analysis of WHO mortality database
Aliasghar A. Kiadaliri1*, Anthony D. Woolf2 and Martin Englund1,3
Abstract
Background: Due to low mortality rate of musculoskeletal disorders (MSK) less attention has been paid to MSK as
underlying cause of death in the general population. The aim was to examine trend in MSK as underlying cause of
death in 58 countries across globe during 1986–2011.
Methods: Data on mortality were collected from the WHO mortality database and population data were obtained
from the United Nations. Annual sex-specific age-standardized mortality rates (ASMR) were calculated by means of
direct standardization using the WHO world standard population. We applied joinpoint regression analysis for trend
analysis. Between-country disparities were examined using between-country variance and Gini coefficient. The
changes in number of MSK deaths between 1986 and 2011 were decomposed using two counterfactual scenarios.
Results: The number of MSK deaths increased by 67% between 1986 and 2011 mainly due to population aging. The
mean ASMR changed from 17.2 and 26.6 per million in 1986 to 18.1 and 25.1 in 2011 among men and women,
respectively (median: 7.3% increase in men and 9.0% reduction in women). Declines in ASMR of 25% or more were
observed for men (women) in 13 (19) countries, while corresponding increases were seen for men (women) in 25 (14)
countries. In both sexes, ASMR declined during 1986–1997, then increased during 1997–2001 and again declined over
2001–2011. Despite decline over time, there were substantial between-country disparities in MSK mortality and its
temporal trend.
Conclusions: We found substantial variations in MSK mortality and its trends between countries, regions and also
between sex and age groups. Promoted awareness and better management of MSK might partly explain reduction in
MSK mortality, but variations across countries warrant further investigations.
Background
Musculoskeletal disorders (MSK) cover a wide range of
disorders affecting joints, bones, muscles and soft tissues.
Many MSK are recurrent or lifelong disorders [1]. The
main consequences of MSK are typically long term pain,
physical disability, loss of independence, reduced social
interaction, and a decline in quality of life [2]. Globally,
18.5% of years lived with disability was attributed to MSK
in 2015 (68% increase from 1990) [3]. When taking into
account both death and disability, all MSK combined
accounted for 6.0% of the total global disability-adjusted
life years [4]. Population growth, ageing, obesity, increased
sedentary lifestyles, and work-related issues imply that the
number of people suffering from MSK (and, thus the bur-
den from MSK) will increase dramatically worldwide over
the coming decades [5].
Increased risk of mortality may be another conse-
quence of MSK, even though for the majority of MSK
the mortality rate is low. Despite this, to have an accur-
ate estimation of burden of MSK, mortality associated
with MSK must also be measured [1]. Previous studies
reported higher risk of mortality among people with
some MSK including rheumatoid arthritis (RA) and
osteoarthritis (OA) compared with the general popula-
tion possibly due to increased risk of cardiovascular
disease and infection [6–10]. However, due to low
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mortality rate less attention has been paid to MSK as
underlying cause of death in the general population.
To our best knowledge, only a recent study investi-
gated temporal trend in mortality with MSK as under-
lying cause in Sweden [11]. MSK mortality has been
influenced by the emergence of new advances in MSK
management including introduction of biological agents
for RA. For example, previous studies reported that bio-
logical agents are associated with increased risk for ser-
ious infectious events and declined risk of cardiovascular
events [12–14]. Considering this new advances and also
scarcity of study on MSK mortality, an update on the
trends in MSK mortality is needed. In addition, we
quantified the magnitude of the absolute and relative
between-country disparities in MSK mortality which has
important policy implications. Furthermore, we decom-
posed changes in number of MSK deaths into demo-
graphic and epidemiologic changes which are important
in health systems policy making. The aim of the current
study was to investigate the trends in MSK mortality
rates and associated between-country disparities using




Annual data on all-cause mortality and mortality due to
MSK as underlying cause of death during 1986–2011
were obtained from the WHO mortality database
(http://www.who.int/healthinfo/mortality_data/en/,
accessed April 2016). This database provides annual data
on underlying cause of death by age, sex, and cause of
death as submitted by national death registration systems.
International Classification of Diseases (ICD) codes were
used to extract data on MSK mortality (ICD-8 and ICD-9
codes 710–740, and ICD-10 codes M00-M99). Several
countries used different codes for MSK deaths which was
taken into account in extracting the data. Due to low
number of MSK deaths, we only included countries with
more than one million population in 2010. In total, 58
countries (United Kingdom included as three countries:
England & Wales, Northern Ireland, and Scotland) had re-
quired data for our analysis and were included. The appli-
cation of ICD revisions varied across countries during the
study period (Additional file 1: Table S1).
While there were no missing data for 49 countries, in 9
countries missing data points ranged from one in
Kazakhstan and Dominican Republic to 6 in Panama
resulting in a total of 42 missing values out of 3016 sex-
country-year data points. Missing values were imputed
using multiple imputation (10 imputations) applying Pois-
son regression model adjusted for year, sex, age group,
and ICD revision with population as exposure (number of
deaths was used as dependent variable). Population data
by sex and age were obtained from the United Nations
Population Prospects database (http://esa.un.org/unpd/
wpp/). Moreover, we grouped these countries in 10 re-
gions according to the United Nations Statistics Division
(http://unstats.un.org/unsd/methods/m49/m49regin.htm):
Asia (n = 7), Eastern Europe (n = 8), Northern Europe
(n = 11), Southern Europe (n = 6), Western Europe (n = 6),
Caribbean (n = 4), Central America (n = 4), South America
(n = 8), North America (n = 2), and Oceania (n = 2).
Trend analysis
We computed age-standardized mortality rates per mil-
lion population by means of direct standardization using
the WHO Reference Population [15]. Age-standardized
rates per million population were calculated for each
country/region and year for each sex. We also computed
women to men age-standardized rate ratio and its 95%
confidence interval (CI). The percent change was calcu-
lated as the difference between the rate of 1986 and
2011 divided by the rate of 1986.
Temporal trends in age-standardized mortality rate
were analyzed by joinpoint regression using the Join-
point Regression Program version 4.2.0.2 from the Sur-
veillance Research Program of the US National Cancer
Institute (http://surveillance.cancer.gov/joinpoint). Join-
point regression identifies points with a significant
change in trend (“joinpoints”) and determined linear
trends between joinpoints. In the software a series of
permutation tests is applied to compute the number of
joinpoints to best fit the data [16]. For each joinpoint an
annual percentage change (APC) is estimated by fitting a
regression line to the natural logarithm of the age-
standardized rates, using calendar year as a predictor.
The average annual percent change (AAPC) as the
weighted average of APCs was computed to provide a
summary measure of the trend for the whole time period
[17]. Since recent trends are possibly the best predictor
of mortality rates in coming years and also to avoid
biases caused by differences in ICD revision, we add-
itionally computed the percentage changes and AAPCs
for period 2001–2011.
Between-country disparity
We used between-country variance (BCV) to examine the
trend in absolute between-country disparity in MSK mortal-






Where pj is country j’s proportion of the total popula-
tion, y is country j’s age-standardized MSK mortality
rate, and μ is the pooled age-standardized MSK mortal-
ity rate of all countries.
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Gini coefficient was used for examining changes in
relative between-country disparities. Gini coefficient is a
commonly used disparity measure [18] and is based on
the Lorenz curve which plots the cumulative share of
population ranked by health variable, in an increasing
order, against the cumulative share of health variable.
The Gini coefficient is equal to twice the area between
the Lorenz curve and diagonal. Its value ranges from 0
(perfect equality) to one (maximum possible inequality).
Decomposition analysis
We decomposed the drivers of changes in the number
of MSK deaths between 1986 and 2011 into three com-
ponents using two counterfactual scenarios [19]: 1)
population growth scenario using the number of popula-
tion in 2011 and the age-sex structure and MSK death
rates in 1986, 2) population growth and aging scenario
using the number of population and the age-sex struc-
ture in 2011 and MSK death rates in 1986. Difference
between the actual number of deaths in 1986 and those
estimated from the population growth scenario is the
change due to population growth. The difference be-
tween the population growth scenario and population
growth and aging scenario is the change due to popula-
tion aging. The difference between the actual number of
deaths in 2011 and the population growth and aging sce-
nario is the change due to epidemiologic changes. The
epidemiologic changes are changes in the age-, sex-, and
cause-specific rates of death and include all changes in
mortality that cannot be explained by population growth
and aging. The actual change in the number of deaths
between 1986 and 2011 is equal to the net change in
these three components.
Results
Number of deaths and proportion of all causes deaths
In total, 192 666 069 men and 177 582 994 women died
in 58 countries during 1986–2011, of these 419 848 men
and 956 011 women died with MSK as underlying cause.
About 70 and 75% of all MSK deaths were observed in
men and women aged 65 years and older, respectively. On
average, MSK deaths constituted 0.22% (ranging from
0.02% in Romania to 0.48% in Spain) and 0.54% (ranging
from 0.05% in Romania to 1.28% in Spain) of all-cause
deaths among men and women, respectively. Among
men, MSK deaths increased from 11861 deaths in 1986
(0.18% of all-cause deaths) to 22380 deaths in 2011 (0.28%
of all-cause deaths, Additional file 2: Figure S1), represent-
ing an increase of 89% (ranging from 85.3% reduction in
Romania to 2600% increase in Greece). Among women,
MSK deaths increased from 28 272 in 1986 (0.46% of all-
cause deaths) to 44 652 in 2011 (0.61% of all-cause
deaths), corresponding to an increase of 58% (ranging
from 71.9% reduction in Romania to 552.9% increase in
Greece). Across regions, the highest reduction in the
number of MSK deaths between 1986 and 2011 was seen
in Eastern Europe for men and in Northern Europe for
women. South America had the highest increases in the
number of MSK deaths for both sexes.
Age-standardized mortality rate
The pooled age-standardized MSK mortality rates were
17.7 and 26.5 deaths per million person-years among
men and women, respectively (women to men rate ratio
of 1.5). The mean MSK mortality rates ranged from 2.6
deaths per million person-years in Romania to 45.3 in
Trinidad and Tobago for men, and from 4.4 in Bulgaria
to 68.9 in Trinidad and Tobago for women (Fig. 1). In
all countries but Guatemala and Greece, women had sta-
tistically significantly higher MSK mortality rate than
men (Additional file 1: Table S2). Among regions, the
highest and lowest MSK mortality rates for both sexes
were observed in Central America and Eastern Europe,
respectively (Additional file 3: Figure S2).
The mean MSK mortality rate increased from 17.2
deaths per million person-years in 1986 to 18.1 in 2011
for men, representing a 5.3% increase (ranging from an
86% reduction in Panama to a 1325% increase in Greece
with a median of 7.3% increase, Table 1). Mortality reduc-
tions of 25% or more were observed in 13 countries, while
increases of 25% or more were seen in 25 countries. The
absolute change in MSK mortality rate ranged from about
50 less deaths per million person-years in Guatemala to
about 19.5 more deaths in Greece between 1986 and
2011. Across regions, the highest MSK mortality decline
was observed in Central America (28% reduction) and the
highest increase in Caribbean (58% increase). Between
1986 and 2011, age-specific MSK mortality rate declined
in men 0–19 years and 65–74 years and increased in all
other age groups (Fig. 2).
For women, the mean MSK mortality rate declined
from 26.6 deaths per million person-years in 1986 to
25.1 in 2011, representing a 5.6% reduction (ranging
from a 76.5% reduction in Singapore to a 233% increase
in Greece with a median of 9.0% reduction). Mortality
decreases of 25% or more were observed in 19 countries,
while corresponding increase were seen in 14 countries.
The absolute change ranged from 30.5 less MSK deaths
per million person-years in England & Wales to about
34 more deaths in Colombia between 1986 and 2011.
Across regions, the highest MSK mortality decline was
seen in Northern Europe (41.1% reduction) and the
highest increase in South America (40.5% increase).
Age-specific MSK mortality rates declined in most age
groups with the highest decline and increase for 0–9
years and 25–29 years age groups, respectively.
In 39 out of 58 countries women experienced more
favorable changes (i.e., either more reductions or less
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increases) compared with men. In addition, the absolute
differences in MSK mortality between women and men de-
clined from 9.4 deaths per million person-years in 1986 to
6.9 deaths in 2011. Corresponding women to men rate ratio
(95% CI) declined from 1.54 (1.51 to 1.58) to 1.38 (1.36 to
1.40) during the same period. Moreover, in 15 out of 18 age
groups, women experienced more favorable changes in
age-specific MSK mortality rates compared with men.
Joinpoint Regression analysis
The pooled MSK mortality rate decreased between 1986
and 1997, then increased during 1997–2001 and again
decreased thereafter in both sexes (with lower rate of in-
crease and higher rate of decrease for women compared
with men, Table 1 and Fig. 3). Moreover, while the trend
for whole period revealed statistically non-significant an-
nual changes during 1986–2011 (0.2% annual increase
and 0.3% annual decrease for men and women, respect-
ively), the recent trend (2001–2011) showed a statisti-
cally significant reduction of 0.3% and 1.2% per year
among men and women, respectively. However, there
were substantial between-country variations in temporal
trend (Additional file 4: Figure S3 and Additional file 1:
Table S3). During 1986–2011, the highest annual reduc-
tion was observed in Romania and highest annual in-
crease in Greece for both sexes. On the other hand,
during the most recent decade the highest reduction was
observed among women in Republic of Moldova (9.9%
annual reduction) and the highest increase among men
in Czech Republic (15.0% annual increase).
Between-country disparities
The between-country variance in MSK mortality declined
from 131.4 and 207.2 death per million person-years in
1986 to 73.3 and 181.6 in 2011 among men and women,
respectively (Fig. 4). In all study years, the magnitude of
the between-country variance was higher among women
compared with men. The relative between-country dispar-
ity measured by Gini coefficient declined from 0.33 and
0.28 in 1986 to 0.25 and 0.26 in 2011 among men and
women, respectively. While during 1986–1999, the magni-
tude of relative between-country disparities were higher
among men compared with women, there were lower dis-
parities among men thereafter.
Decomposition analysis of the number of MSK deaths
In 2011, the number of MSK deaths increased by 67%
compared to 1986 and this was mainly due to popula-
tion aging (Fig. 5). In six regions the number of MSK
deaths increased due to population growth and aging
and declined due to epidemiologic changes, but only in
Northern Europe this led to an actual decline in the
number of MSK deaths. In Eastern Europe the combin-
ation of increase in the number of MSK deaths due to
aging population and declines due to population growth
and epidemiologic changes translated into a 9% reduc-
tion in the number of MSK deaths. In Caribbean, South
America, and North America number of MSK deaths
due to all three components increased.
Across countries, the number of MSK deaths due to
population growth, aging and epidemiologic changes
Fig. 1 The mean age-standardized musculoskeletal disorders mortality rates per million person-years, 1986–2011
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increased in 26 countries (Additional file 1: Table S4).
In twenty countries despite the declines due to popu-
lation growth (4 countries) or epidemiologic change
(16 countries), the total number of MSK deaths
increased between 1986 and 2011. A total of 12 co-
untries presented reductions in the total number of
MSK deaths which caused due to either epidemiologic
change (Singapore, Poland, Finland, England & Wales,
Guatemala, and Panama) or population growth (Estonia) or
both (Republic of Moldova, Romania, Russian Federation,
Ukraine, and Lithuania).
Discussion
From 1986 to 2011, on average across all countries, the
total number of MSK deaths and its proportion from all-
cause deaths increased in both sexes and this increase
was mainly due to population aging. In addition, the
age-standardized MSK mortality rate increased by 5.3%
in men and declined by 5.6% in women during the same
period. Although more women died from MSK compared
with men, women experienced more favorable changes
during the study period. While there were substantial rela-
tive and absolute disparities in MSK mortality between
Fig. 3 Temporal trend in age-standardized musculoskeletal mortality rates across regions, 1986–2011. Footnote: Symbols display observed values
and solid lines show fitted values from joinpoint regression
Fig. 2 Percent change in age-specific musculoskeletal mortality rates per million person-years between 1986 and 2011
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countries, these disparities have declined over time with
more profound reduction among men.
The total number of MSK deaths increased due to
population growth and aging without a significant reduc-
tion due to epidemiologic changes. Across regions while
MSK deaths due to epidemiologic changes declined in
most regions, these reductions led to actual reductions in
MSK deaths only in Eastern and Northern Europe. These
findings highlight importance of these demographic forces
particularly aging in MSK deaths which should be taken
into account by health policy-makers. It should be noted
that changes in ICD revision and quality of vital reg-
istrations are included in epidemiologic changes and
might partly offset reductions due to other epidemiologic
changes including improvement in MSK management.
We found substantial variations between regions/coun-
tries not only in level of MSK deaths but also in temporal
changes of MSK deaths. For example, MSK deaths in-
creased in Southern Europe, Caribbean, Central America,
and South America over recent decade. Differences be-
tween regions/countries in availability and access to treat-
ments, socioeconomic status, prevalence of MSK risk
factors including obesity, epidemiology of disease, quality
of vital registration, and cause of death certification in-
cluding transition from paper to electronic certification
and from manual to automated coding system might par-
tially explain these disparities. Moreover, previous studies
reported racial disparities in prevalence of musculoskeletal
disorders and access to treatment which might partially
explain the observed disparities in our study [20–22].
Fig. 5 Percent change in number of musculoskeletal disorders deaths due to population growth, population aging, and epidemiologic
changes, 1986–2011
Fig. 4 Changes in absolute and relative between-country disparities in musculoskeletal disorders mortality rate over time, stratified by sex
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Furthermore, although both relative and absolute
between-country disparities have declined over time still
substantial disparities are present. This is particularly of
concern among women where compared with men the
relative inequality slightly declined between 1986 and
2011 (5% reduction among women vs. 24% reduction
among men). It should be noted that the observed dispar-
ity in recent decade cannot be attributed to between-
country differences in ICD revision since many countries
(46 out of 58 countries) were applying the same ICD revi-
sion during 2001–2011. Further analyses are required to
investigate these disparities in more details.
The observed increases in pooled MSK mortality rates
during 1997–2001 are possibly due to the introduction
of ICD-10 coding system in many countries (most coun-
tries introduced ICD-10 between 1995 and 2001) consid-
ering that a ICD-10 to ICD-9 comparability ratio greater
than 1 have been reported for MSK deaths [23–25].
While not case for all countries but we observed a jump
in MSK mortality rates in many countries in early years
of introducing ICD-10 revision. This suggests that taking
the impact of ICD-10 introduction into account would
be associated with a steady reduction in pooled MSK
mortality rates over the whole study period. Global focus
on MSK particularly since endorsement of the Bone and
Joint Decade 2000–2010 [26] by the United Nations and
the WHO might partly explain observed reduction in
MSK mortality rate. Moreover, new interventions par-
ticularly the biologic agents for RA, emergence of new
imaging technologies, and advances in the rapid surgical
procedures substantially changed the clinical manage-
ment of patients and might partially explain the ob-
served declining trend in MSK mortality rates [2]. This
decline in mortality rate alongside population aging
imply potential increases in burden of MSK in coming
years and health policy-makers should be aware of this.
Several strategies has been suggested in response to this
expected increase in burden of MSK including raising
patients’ awareness about importance of a healthy life
style, raising awareness of health professionals through
providing adequate training in MSK, early diagnosis and
treatment of MSK, improving access to MSK therapies
including rehabilitation, implementation of integrated
and patient-centred multi-disciplinary models of care,
and delivery of primary prevention initiatives at a popu-
lation level [6, 27–29].
Almost in all countries women had higher MSK mor-
tality rate compared with men. Several explanations have
been suggested for this sex disparity including higher
prevalence of MSK among women, sex differences in
biological and hormonal factors, in severity and remis-
sion from MSK, in access and responses to treatments,
and in susceptibility developing other complications
such as cardiovascular disease [30–35]. While sex
disparity in MSK mortality declined over the study
period, substantial effort and resources are required to
close the observed gap. For example, if we naively as-
sume that men will continue to have an annual reduc-
tion of 0.3% observed in 2001–2011 until 2025, then the
annual reduction among women should be doubled
(from 1.2 to 2.6%) to close sex disparity in MSK mortal-
ity rate by 2025.
In interpreting the results of the current study, several
limitations should be considered. First, MSK are under-
reported as underlying cause of deaths on death certifi-
cates and the degree of underreporting might vary
between time and space that could bias our findings.
Similarly, there are between country/time variations in
presence of errors or incompleteness in death certificates
which might bias our results. Second, changes in the
death certification, coding process over time (e.g., a tran-
sition from paper to electronic certification, from man-
ual to automated coding system, from ICD-9 to ICD-10)
might bias the results of mortality trends. For example,
considering a ICD-10 to ICD-9 comparability ratio
above 1, our estimates for countries with declining
trends are possibly an underestimation of the magnitude
of the true trend, and for countries with increasing trend
our estimates could be either an overestimation of the
magnitude of the true trend or a bias in direction of
change. However, without knowing the country-specific
comparability ratios it is hard to quantify the size of
biases in our estimations. Furthermore, it should be
noted that this differences in ICD revision could not ac-
count for the observed disparities in most recent decade
since most countries were applying ICD-10 revision over
this period. Third, due to lack of data we were not able
to investigate mortality of MSK subcategories. For ex-
ample, only 29 (mostly European countries) out of 58
countries had the required data on mortality of RA over
the study period (in these countries RA constituted 22%
of all MSK deaths). Fourth, the countries included in
our study were mainly upper-middle and high income
countries with a reliable vital registration system and
available data on WHO mortality database and therefore
our results might not be generalizable to lower-middle
and low income countries. Fifth, the small number of
deaths in some countries might have limited the power
of our study to detect significant joinpoints over the
study period. In addition, direct age-standardization
method used in the study is sensitive to small number of
events and the results for countries with low number of
events should be interpreted with caution. It also should
be noted that the WHO standard population was devel-
oped in 2001 and might not reflect demographic
changes occurred since 2001. Furthermore, the disparity
measures applied in the study are sensitive to outliers
and cannot capture socioeconomic gradient in MSK
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mortality. Sixth, this is a descriptive aggregate-level study
and no causal inferences should be made from the find-
ings. Despite these limitations, to our best knowledge, this
is the first study to investigate temporal trend and
between-country disparities in MSK mortality across a
large number of countries. The results of the current
study might provide useful insights on epidemiological
status of MSK and can be used by policy-makers in plan-
ning MSK management at both national and global level.
Conclusion
The total number of MSK deaths and its proportion
from all-cause deaths increased between 1986 and 2011
and this was mainly due to population aging. On the
other hand, taking the potential impact of ICD-10 revi-
sion into account, the pooled mean age-standardized
MSK mortality rate declined over the study period with
a more favorable reduction among women. The highest
MSK mortality rates were observed in Central America
and the lowest in Eastern Europe. Between 1986 and
2011, the highest reduction in MSK mortality rate was
observed in women in Northern Europe and the highest
increase in men in Caribbean. Increases in MSK mo-
rtality rates in Southern Europe, Caribbean, Central
America, and South America during most recent decade
require further actions. Further investigations are re-
quired to explain substantial absolute and relative dis-
parities in MSK mortality rate and its temporal trend
between sexes, countries, and regions.
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